Found 12447 matches for
The 5-year programme award will support research on the DNA repair mechanisms that protect cancer cells from therapy, informing the development of future treatments.
Haematopoietic stem cells (HSCs) support blood system homeostasis and are also used clinically in cell and gene therapies. We are interested in studying the biology of this important stem cell population and developing new HSC-based therapies.
We study the embryonic origins of blood stem cells with the aim to inform the generation of these cells in culture, and ultimate produce clinically relevant blood stem cells for therapeutic purposes.
We are interested in (1) Applying state-of-the-art single cell approaches to study normal and malignant megakaryocyte biology and bone marrow fibrosis, to identify new targets for therapy for patients with myeloproliferative neoplasms; and (2) The role of platelets as biomarkers for early cancer detection.
We use state-of the-art molecular and computational approaches to understand mechanisms of intestinal immunity and how those go wrong in the inflammatory bowel diseases, Crohn’s disease and Ulcerative Colitis.
Our group is interested in developing novel immunotherapeutic approaches for leukaemia. Clinical approaches currently used include allogeneic haematopoietic stem cell transplantation, chimeric antigen receptor T cell therapy and immune checkpoint inhibitors. While each of these approaches can be successful, they also fail in many patients as a result of tumour adaptations or diminished function of immune cells. Enhanced immunity can also lead to immune-related adverse events due to on- or off-target effects. We are exploring the mechanisms that underpin these failures and using this information to devise new strategies that can be translated into early phase clinical trials.
We are investigating the link between human fetal haematopoiesis and the origin and biology of childhood leukaemia. In particular, we are interested in the pathogenesis of infant leukaemia, which is a refractory disease that invariably originates in utero.
The Haematopoietic Stem Cell Biology (HSCB) Laboratory is focused on understanding how the normal haematopoietic stem/progenitor hierarchy is disrupted during the development of myeloid malignancies. Our overarching aim is to improve the management of myeloproliferative neoplasms and related conditions through better monitoring and therapeutic targeting of malignant stem cell populations.
Research in the Jacobsen group is focused at unravelling normal and malignant hematopoietic stem and progenitor cell biology at the single cell level.
We are primarily interested in understanding how the genome functions and to leverage this to develop novel genome editing based cellular therapies
We study endogenous DNA damage caused by metabolites and their impact on the function of vertebrate stem cells and the ageing process
Centre for Computational Biology
In the last decade biology has become a data-rich science. However, turning these data into an understanding of biology and disease remains challenging. Our group develops novel analytical methods to address a range of specific problems in genetics and sequence analysis, with the eventual goal to better understand the genetic basis of human biology in health and disease.
Centre for Computational Biology
We are a computational biology research group using genomic and functional genomic data to study transcriptional regulation in neuroscience.
Targeting hypoxia metabolism and angiogenesis for synthetic lethality.
We focus on systems level “big picture” approaches to understand gene regulation and build gene regulatory networks during development and disease in zebrafish, chick, lamprey and human models.
We are using an integrated approach to create synthetic systems capable of rewiring or enhancing naturally-evolved cellular behaviours, and apply the emerging conceptual frameworks to advance somatic and stem cell engineering approaches for basic research and therapeutic applications.
Centre for Computational Biology MRC MHU
Using genomics, computational and synthetic biology approaches to understand how genes are regulated in health and disease.
Hematopoietic stem cell (HSC) transplantation is the only stem cell therapy in routine clinical use, and it is also the cell type that gives rise to most blood cancers. We use single cell biology and genetics to understand how hematopoietic stem cells normally sustain blood formation, and how this process is altered during ageing and when leukemia develops.